logo image

Cisplatin information from DrugsUpdate  

See Available Brands of Cisplatin in India

P - Contraindicated in pregnancy
L - Contraindicated in lactation

Cisplatin, cisplatinum, or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas, and germ cell tumors. It was the first member of a class of anti-cancer drugs which now also includes carboplatin and oxaliplatin. These platinum complexes react in vivo, binding to and causing crosslinking of DNA which ultimately triggers apoptosis (programmed cell death).



Cisplatin modifies cell cycle by interfering with DNA structure and function. Effects are most prominent during the S phase but cells are killed at all stages. Cisplatin synergises with other anticancer drugs e.g. fluorouracil. It has a narrow therapeutic margin and is highly toxic.

Well absorbed (intraperitoneal).

Concentrated in the liver, kidneys, large and small intestines; poor penetration into the CNS.

Urine. Elimination half-life: 25-49 minutes (initial), 58-73 hours (terminal).

Cisplatin Indications / Cisplatin Uses

Information Not Available

Cisplatin Adverse Reactions / Cisplatin Side Effects

Severe nausea and vomiting. Serious toxic effects on the kidneys, bone marrows and ears. Hypomagnesaemia, hypocalcaemia, hyperuricaemia. Peripheral neuropathies, papilloedema, optic neuritis, seizures. Ototoxicity (children) manifested as tinnitus, loss of hearing, deafness or vestibular toxicity.

Potentially Fatal: Rarely, renal damage due to inadequate hydration during therapy. Very rarely life-threatening myelosuppression. Anaphylactoid reactions (rare) and cardiac abnormalities.



Overdose/confusion with carboplatin
Doses above 100 mg/m 2 /cycle once every 3 to 4 weeks rarely used. Avoid confusion with carboplatin or prescribing practices that fail to differentiate daily doses from total dose per cycle.

Marked nausea and vomiting occur in almost all patients and are occasionally so severe that the drug must be discontinued.

Myelosuppression occurs in 25% to 30% of patients. Leukopenia and thrombocytopenia are more pronounced at doses above 50 mg/m 2 . Anemia (decrease of 2 g hemoglobin/dL) occur at the same frequency and with the same timing as leukopenia and thrombocytopenia.

Anaphylactic-like reactions have occurred.

Has occurred in no more than 31% of patients given a single dose of 50 mg/m 2 . It is manifested by tinnitus or loss of high frequency hearing, and occasionally deafness. May be pronounced in children.

Renal toxicity

Dose-related and cumulative renal insufficiency is the major dose-limiting toxicity. This is manifested by elevations in BUN and creatinine, serum uric acid, or a decrease in Ccr. Renal toxicity becomes more severe and prolonged with repeated courses; therefore, renal function must return to normal before another dose can be given. Amifostine can be used to reduce renal toxicity in patients with advanced ovarian cancer receiving repeated doses of cisplatin.

Special Precautions

Patients with renal or hepatic disorder, myelosuppression. Monitor renal, neurological and auditory function. Perform blood counts regularly. Maintain adequate hydration before and 24 hours after admin to minimise nephrotoxicity.

Other Drug Interactions

Synergistic with 5-fluorouracil and etoposide. Efficacy increased and toxicity reduced when combined with radioprotecting agent WR 2721. At doses ≤100 mg, cisplatin is an ideal drug to combine with other cytotoxic drugs; unlike other antineoplastic drugs, it causes little myelosuppression.

Potentially Fatal: Potentiates nephrotoxicity with aminoglycosides. Increased toxicity when combined with other cytotoxic drugs.

Other Interactions

Information Not Available


Metastatic ovarian cancer
Adult: As monotherapy: 100 mg/m2 per cycle, given as a single dose infused in 0.9% sodium chloride or glucose once every 4 weeks.
For combination therapy with cyclophosphamide: 75-100 mg/m2 on day 1 of every 4-week cycle.
Renal impairment: Dose adjustment may be needed.

Metastatic testicular tumours
Adult: 20 mg/m2 BSA daily for 5 days per cycle.
Renal impairment: Dose adjustment may be needed.

Advanced bladder cancer
Adult: 50-70 mg/m2 per cycle once every 3-4 weeks, depending on the extent of prior exposure to radiation and/or chemotherapy treatment. An initial dose of 50 mg/m2 every 4 weeks may be used in heavily pre-treated patients.
Renal impairment: Dose adjustment may be needed.

Y-site incompatibility: Thiotepa, cefepime, amphotericin B, amifostine, piperacillin/tazobactam, cholesteryl sulfate complex.
Admixture incompatibility: Mesna, thiotepa, fluorouracil.


Information Not Available

List of Contraindications

Cisplatin and Pregnancy

Contraindicated in pregnancy.

Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).

Cisplatin and Lactation

Contraindicated in lactation

Cisplatin and Children

Information Not Available

Cisplatin and Geriatic

Information Not Available

Cisplatin and Other Contraindications

Patients with severe renal or auditory disorder, known hypersensitivity, severe bone marrow suppression, peripheral neuropathy, pregnancy, lactation.


Store at 15-25°C.


Lab interference

Store at 15-25°C.


© 2011-2020 DrugsUpdate.com. Disclaimer | Site Map

  • Companies that own platforms will own the market
  • Trusted and recognized by all Doctors
  • Access to Millions of Visitors instantly.
  • Companies that own platforms will own the market
  • Trusted and recognized by all Doctors
  • Access to Millions of Visitors instantly.